Egetis Therapeutics AB (LSE:0ABW) has received US Food and Drug Administration approval for EMCITATE (tiratricol) in MCT8 deficiency, making it the first FDA-approved treatment for the rare genetic disorder. The FDA also granted the company a Rare Pediatric Disease Priority Review Voucher, which Egetis expects to explore monetising in the fourth quarter of 2026.
What was announced
Egetis Therapeutics (LSE:0ABW), the Stockholm-headquartered rare disease company with operations in the US and Europe, announced on 28 September 2026 that the FDA has approved EMCITATE (tiratricol). The approved indication is the treatment of peripheral thyrotoxicosis in adult and paediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome.
EMCITATE is a thyroid hormone receptor agonist. According to the company, it is the first and only treatment approved by the FDA for MCT8 deficiency. The label states that it is not intended for primary hypothyroidism and carries a boxed warning against use for obesity or weight loss. The most common adverse reactions, occurring in at least 5% of patients, were diarrhoea, vomiting, rash and hyperhidrosis, and signs of thyrotoxicosis are monitored during dose titration.
Egetis said EMCITATE now holds Marketing authorisations in both the European Union and the United States.
The evidence and the disease
The approval was supported by a clinical development programme that included the ReTRIACt trial, Triac Trial I and Triac Trial II, the Erasmus Medical Center cohort study and survival study, and a US expanded access programme.
MCT8 deficiency is a rare, X-linked disorder caused by mutations in the SLC16A2 gene, which impair the function of the MCT8 thyroid hormone transporter. The company said this leads to insufficient thyroid hormone activity in the central nervous system combined with excessive exposure to the thyroid hormone T3 in the rest of the body. Manifestations include severe neurodevelopmental impairment, peripheral thyrotoxicosis, failure to thrive, cardiovascular strain and muscle wasting. Median life expectancy is about 35 years, according to the announcement. Patient numbers in the US were not disclosed.
Chief executive Nicklas Westerholm said: "Today marks a turning point for patients living with MCT8 deficiency and caregivers who have awaited treatment approval." Dr Andrew J. Bauer, a principal investigator, said the approval "provides physicians the first approved treatment option for patients with MCT8 deficiency". The MCT8-AHDS Foundation said: "This approval demonstrates what's possible when a community unites toward advancing care."
Launch plans and priority review voucher
Egetis expects EMCITATE to be commercially available in the US within eight to ten weeks of approval. Patient access will be supported through the Egetis RareLink programme, with PANTHERx Rare providing specialty pharmacy services including medication access, education and care coordination. The announcement sets out a dedicated US telephone line for patients and physicians seeking support.
The FDA also granted Egetis a Rare Pediatric Disease Priority Review Voucher. Such vouchers entitle the holder to a faster FDA review of a future marketing application and can be sold to other drug developers. Egetis said it expects to explore monetising the voucher in the fourth quarter of 2026, subject to market conditions. No expected sale price or valuation was given.
The announcement did not disclose US pricing for EMCITATE, sales expectations, or the company's cash position and funding requirements for the launch.
What to watch next
Egetis scheduled an analyst and investor call for 8:00am CEST on Tuesday 29 September 2026. Further milestones highlighted by the company are the US commercial launch within the stated eight-to-ten-week window and any agreement to sell the priority review voucher, which the company has indicated it may pursue in the fourth quarter. Details of any such transaction, including its value, would be expected to be announced separately if it takes place.






Please wait processing your request...